Prevalence of Metabolic Syndrome Components in an Urban Mexican Sample: Comparison between Two Classifications
Table 2
Demographic, clinical, and biochemical features of subjects with and without metabolic syndrome included in the study.
MS+
MS−
Subjects (%)
607 (70%)
247 (30%)
Gender (%)
Man
200 (33.0%)
74 (30.0%)
Women
407 (67.0%)
173 (70.0%)
Age (years)
53.4 ± 11.0
49.3 ± 13.4
Body mass index (kg/m2)
29.9 ± 4.8
26.7 ± 4.2
Waist circumference (cm)
97.3 ± 10.8
88.5 ± 11.5
Triglycerides (mg/dL)
233.8 ± 220.7
129.0 ± 7.3
HDL-C (mg/dL)
36.02 ± 9.0
48.0 ± 13.7
Total cholesterol (mg/dL)
211.8 ± 61.5
205.8 ± 42.4
FPG (mg/dL)
158.3 ± 48.1
94.8 ± 16.9
Fibrinogen (mg/dL)
377.0 ± 89.2
3 69.1 ± 71.5
Uric Acid (mg/dL)
5.4 ± 2.8
3.9 ± 1.3
hs-CRP (mg/dL)
1.02 ± 0.5
0.78 ± 0.22
HbA1c (%)
5.0 ± 2.6
4.3 ± 2.1
Currents smoking (%)
136 (22.4)
45 (18.2)
Blood pressure ≥130/≥85 mmHg or previous diagnosis of hypertension
(%)
301 (49.58)
Previously diagnosed hypertension = (%)
282 (46.45)
23 (30.2)
New cases of hypertension = (%)
19 (3.13)
Elevated fasting glucose ≥100 mg/dL or previous diagnosis of T2DM
(%)
398 (65.56)
Previously T2DM = (%)
165 (27.18)
33 (30.2)
New cases of T2DM = (%)
26 (4.28)
No T2MD patients with FPG ≥100 mg/dL–125 mg/dL = (%) 209 (34.43)
FH of AT (%)
112 (18.45)
30 (14.5)
HDL-C = high-density lipoprotein cholesterol, FG = fasting glucose, hsCRP = high sensitivity C protein reactive, HbA1c = glycosylate hemoglobin, T2DM = type 2 diabetes mellitus, IDF = International Diabetes Federation, AHA/NHLBI = American Heart Association/National Heart, Lung, and Blood Institute, FH of EAT = familial history of atherothrombosis.
